Skip to main content
Premium Trial:

Request an Annual Quote

Owkin Licenses EP2, EP4-Targeted Immunotherapy Agent from Idorsia

NEW YORK – Owkin said on Thursday it has licensed EP2 and EP4 inhibitor OKN4395 from Idorsia, unveiling the first therapeutic candidate in its pipeline.

The firm used its artificial intelligence platform to analyze multimodal patient data to create signatures of EP2/EP4 biology that helped identify actionable biomarkers to guide clinical development of OKN4395. Owkin also used its platform to explore therapeutic combinations with OKN4395 that had the most promise of success. Financial details of the licensing agreement were not disclosed.

"Our AI engines integrated rich multimodal patient data from multiple cancer indications, allowing us to discover that EP2/EP4 biology significantly perturbs T-cell connectivity within the tumor microenvironment through direct and indirect mechanisms," Vassili Soumelis, Owkin chief medical officer, said in a statement.

OKN4395, which is in preclinical studies, will initially be studied in solid tumors. Owkin will apply AI to build an external control arm in the drug's Phase Ib trial and use multimodal patient data to select optimal inclusion and exclusion criteria.

Researchers from Idorsia presented preclinical data in 2023 on OKN4395, previously called ACT-1002-4391, which demonstrated the drug could modulate immune cell proliferation and function and that it had single agent anti-tumor efficacy.